Keywords: Pozen, Treximet, Royalty rights, CPPIB Credit, GlaxoSmithKline

Pozen sells future royalty rights to Treximet for $75 million

Article | 28 November 2011

Print This

USA-based Pozen (Nasdaq: POZN) has entered into an accord with Canada’s CPPIB Credit Investments (CII) to sell the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in